An Individualized, Less-Invasive Surgical Approach Algorithm Improves Outcome in Elderly Patients Undergoing Mitral Valve Surgery

Autor: Ulvi Cenk Oezpeker, Fabian Barbieri, Daniel Höfer, Can Gollmann-Tepeköylü, Johannes Holfeld, Florian Sommerauer, Julian Wagner, Sasa Rajsic, Suat Ersahin, Nikolaos Bonaros, Michael Grimm, Müller Ludwig

Publikováno v: Journal of Cardiovascular Development and Disease, Vol 10, Iss 1, p 28 (2023)

Background: For mitral valve surgery (MVS) in elderly, frail patients with increasing life expectancy, finding the least harmful means of access is a challenge. In the complexity of MVS approach evolution, using three different approaches (mini-thora

Externí odkaz: https://doaj.org/article/32e19994e75a48db9d24b4d0abe7d273

Identification of a novel epitope derived from the cancer-germline antigen, HAGE, displaying both in-vitro and in-vivo immunogenicity

Autor: Pawelec Graham, Rees Robert, Müller Ludmila, McArdle Stephanie, Knights Ashley

Publikováno v: Cancer Cell International, Vol 4, Iss Suppl 1, p S50 (2004)

Externí odkaz: https://doaj.org/article/833ec5453c1040148320e4801cc17647

Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio

Autor: Baur Regine, Müller Lutz von, Alan Mustafa, Voisard Rainer, Hombach Vinzenz

Publikováno v: BMC Cardiovascular Disorders, Vol 6, Iss 1, p 14 (2006)

Abstract Background The significant reduction of angiographic restenosis rates in the ISAR-SWEET study (intracoronary stenting and antithrombotic regimen: is abciximab a superior way to eliminate elevated thrombotic risk in diabetes) raises the quest

Externí odkaz: https://doaj.org/article/06aeadfb61714e508d250a786438f72b

Leukemic survival factor SALL4 contributes to defective DNA damage repair.

Autor: Wang F; Department of Pathology, Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China., Gao C; Department of Pathology, Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Lu J; Department of Pathology, Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Tatetsu H; Department of Pathology, Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Williams DA; Division of Hematology/Oncology, Children's Hospital Boston, Harvard Medical School, Boston, MA, USA., Müller LU; Division of Hematology/Oncology, Children's Hospital Boston, Harvard Medical School, Boston, MA, USA.; Genentech, South San Francisco, CA, USA., Cui W; Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China., Chai L; Department of Pathology, Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Publikováno v: Oncogene [Oncogene] 2016 Nov 24; Vol. 35 (47), pp. 6087-6095. Date of Electronic Publication: 2016 May 02.

Overcoming reprogramming resistance of Fanconi anemia cells.

Autor: Müller LU; Division of Pediatric Hematology/Oncology, Children's Hospital Boston, and Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA., Milsom MD, Harris CE, Vyas R, Brumme KM, Parmar K, Moreau LA, Schambach A, Park IH, London WB, Strait K, Schlaeger T, Devine AL, Grassman E, D'Andrea A, Daley GQ, Williams DA

Publikováno v: Blood [Blood] 2012 Jun 07; Vol. 119 (23), pp. 5449-57. Date of Electronic Publication: 2012 Feb 27.